A Retrospective Study of the Efficacy and Safety of Chemoimmunotherapy in Elderly Patients with Extensive-Stage Small Cell Lung Cancer.

@article{kobayashi2026retrospective,
  title = {{A Retrospective Study of the Efficacy and Safety of Chemoimmunotherapy in Elderly Patients with Extensive-Stage Small Cell Lung Cancer.}},
  author = {Minoru Kobayashi and Satoshi Watanabe and Shinji Hirose and Hiroki Watanabe and Kohei Kushiro and Ryo Suzuki and Naohiro Yanagimura and Miyuki Sato and Tomohiro Tanaka and Koichiro Nozaki and Yu Saida and Jun Arinami and Yuka Goto and Ko Sato and Daisuke Ishikawa and Takao Miyabayashi and Kosuke Ichikawa and Naoya Matsumoto and Jun Koshio and Yoshiki Hayashi and Kenichi Koyama and Masato Makino and Hideyuki Kuriyama and Ryohei Terashima and Atsushi Hashimoto and Toshiaki Kikuchi},
  journal = {Cancers},
  year = {2026},
  month = sep,
  doi = {10.3390/cancers18193131},
  url = {https://europepmc.org/article/MED/42882826},
  note = {CC BY},
}

TY  - JOUR
TI  - A Retrospective Study of the Efficacy and Safety of Chemoimmunotherapy in Elderly Patients with Extensive-Stage Small Cell Lung Cancer.
AU  - Minoru Kobayashi
AU  - Satoshi Watanabe
AU  - Shinji Hirose
AU  - Hiroki Watanabe
AU  - Kohei Kushiro
AU  - Ryo Suzuki
AU  - Naohiro Yanagimura
AU  - Miyuki Sato
AU  - Tomohiro Tanaka
AU  - Koichiro Nozaki
AU  - Yu Saida
AU  - Jun Arinami
AU  - Yuka Goto
AU  - Ko Sato
AU  - Daisuke Ishikawa
AU  - Takao Miyabayashi
AU  - Kosuke Ichikawa
AU  - Naoya Matsumoto
AU  - Jun Koshio
AU  - Yoshiki Hayashi
AU  - Kenichi Koyama
AU  - Masato Makino
AU  - Hideyuki Kuriyama
AU  - Ryohei Terashima
AU  - Atsushi Hashimoto
AU  - Toshiaki Kikuchi
PY  - 2026
DA  - 2026/09/27
JO  - Cancers
DO  - 10.3390/cancers18193131
UR  - https://europepmc.org/article/MED/42882826
AB  - Background/Objectives: We evaluated the efficacy and safety of first-line treatment with a programmed death-ligand 1 (PD-L1) inhibitor plus platinum-based chemotherapy versus chemotherapy alone in patients aged ≥75 years with extensive-stage small cell lung cancer (ES-SCLC). Methods: We retrospectively analyzed the patients with ES-SCLC treated within the Niigata Lung Cancer Treatment Study Group between August 2019 and April 2024. Results: A total of 364 consecutive patients were enrolled. After excluding 21 patients who did not receive treatment or had ineligible histological types, 343 patients were included in the analysis. Of these, 132 were aged ≥75. Compared with chemotherapy alone, administering a PD-L1 inhibitor with chemotherapy significantly improved the median overall survival among elderly patients (13.6 vs. 8.4 months; hazard ratio, 0.543; p = 0.0277). The median progression-free and overall survivals were similar between the ≥75-year and <75-year groups treated with PD-L1 inhibitor plus chemotherapy (4.9 vs. 4.8 months; p = 0.7611 and 13.6 vs. 15 months; p = 0.732, respectively). Immune-related adverse events (irAE) of ≥grade 3 occurred in 4 and 12 patients (p = 0.7823), and non irAE of ≥grade 3 occurred in 47 and 103 patients (p = 0.5247) in the ≥75-years and <75-years subgroups, respectively. Conclusions: In this retrospective study, among patients aged ≥75 years with ES-SCLC, the addition of a PD-L1 inhibitor to platinum-based chemotherapy was associated with longer overall survival. Progression-free and overall survival outcomes were comparable between elderly and younger patients, with no clear age-related difference observed in the incidence of adverse events of ≥grade 3.
SN  - 2072-6694
ER  -